198 related articles for article (PubMed ID: 32667853)
21. Do we have enough evidence to use chloroquine/hydroxychloroquine as a public health panacea for COVID-19?
Palmeira VA; Costa LB; Perez LG; Ribeiro VT; Lanza K; Silva ACSE
Clinics (Sao Paulo); 2020; 75():e1928. PubMed ID: 32401962
[No Abstract] [Full Text] [Related]
22. Use of chloroquine or hydroxychloroquine in treatment of COVID-19: is it ethical?
Allam MF; Andraous F
Cent Eur J Public Health; 2020 Sep; 28(3):246-247. PubMed ID: 32997483
[No Abstract] [Full Text] [Related]
23. Hydroxychloroquine prophylaxis for high-risk COVID-19 contacts in India: a prudent approach.
Tilangi P; Desai D; Khan A; Soneja M
Lancet Infect Dis; 2020 Oct; 20(10):1119-1120. PubMed ID: 32450054
[No Abstract] [Full Text] [Related]
24. Benefit v. risk when using chloroquine in patients with severe COVID-19 disease.
Decloedt EH; Reuter H; Allwood B; Parker A; Koegelenberg CFN; Blockman M; Taljaard J
S Afr Med J; 2020 Apr; 110(5):12903. PubMed ID: 32657706
[No Abstract] [Full Text] [Related]
25. COVID-19 and hydroxychloroquine: Let the available data speak for themselves.
Paliani U; Cardona A
Eur J Intern Med; 2020 Oct; 80():121. PubMed ID: 32709544
[No Abstract] [Full Text] [Related]
26. Hydroxychloroquine prophylaxis for SARS-CoV-2 infection among healthcare workers.
R Karim HM; Ahmed G
Indian J Med Res; 2020 Jul & Aug; 152(1 & 2):119-120. PubMed ID: 32773410
[No Abstract] [Full Text] [Related]
27. Chloroquine and COVID-19: A western medical and scientific drift?
Million M; Roussel Y; Raoult D
Eur J Intern Med; 2020 Aug; 78():4-5. PubMed ID: 32600860
[No Abstract] [Full Text] [Related]
28. Potential of chloroquine and hydroxychloroquine to treat COVID-19 causes fears of shortages among people with systemic lupus erythematosus.
Jakhar D; Kaur I
Nat Med; 2020 May; 26(5):632. PubMed ID: 32269358
[No Abstract] [Full Text] [Related]
29. Hydroxychloroquine prophylaxis for COVID-19 contacts in India.
Rathi S; Ish P; Kalantri A; Kalantri S
Lancet Infect Dis; 2020 Oct; 20(10):1118-1119. PubMed ID: 32311324
[No Abstract] [Full Text] [Related]
30. Chloroquine or Hydroxychloroquine for COVID-19: Is Cardiotoxicity a Concern?
Kamp TJ; Hamdan MH; January CT
J Am Heart Assoc; 2020 Jun; 9(12):e016887. PubMed ID: 32463308
[No Abstract] [Full Text] [Related]
31. COVID-19 prevention and treatment: A critical analysis of chloroquine and hydroxychloroquine clinical pharmacology.
White NJ; Watson JA; Hoglund RM; Chan XHS; Cheah PY; Tarning J
PLoS Med; 2020 Sep; 17(9):e1003252. PubMed ID: 32881895
[TBL] [Abstract][Full Text] [Related]
32. Brief Review of Chloroquine and Hydroxychloroquine Toxicity and Management.
Lebin JA; LeSaint KT
West J Emerg Med; 2020 Jun; 21(4):760-763. PubMed ID: 32726238
[TBL] [Abstract][Full Text] [Related]
33. Safety considerations for chloroquine and hydroxychloroquine in the treatment of COVID-19.
Gevers S; Kwa MSG; Wijnans E; van Nieuwkoop C
Clin Microbiol Infect; 2020 Sep; 26(9):1276-1277. PubMed ID: 32422406
[No Abstract] [Full Text] [Related]
34. Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know.
Yazdany J; Kim AHJ
Ann Intern Med; 2020 Jun; 172(11):754-755. PubMed ID: 32232419
[TBL] [Abstract][Full Text] [Related]
35. Emergency Authorization of Chloroquine and Hydroxychloroquine for Treatment of COVID-19.
Piszczatoski CR; Powell J
Ann Pharmacother; 2020 Aug; 54(8):827-831. PubMed ID: 32389025
[TBL] [Abstract][Full Text] [Related]
36. Ventricular arrhythmia risk due to chloroquine / hydroxychloroquine treatment for COVID-19: Should it be given.
Malviya A
Indian Heart J; 2020; 72(2):131-132. PubMed ID: 32534688
[No Abstract] [Full Text] [Related]
37. Chloroquine and hydroxychloroquine for the prevention and therapy of coronavirus disease 2019: new hopes and old cardiovascular concerns.
Jankowska EA; Sierpiński R; Tkaczyszyn M; Drozd M; Szachniewicz J; Duda-Sikuła M; Knysz B; Simon K; Szenborn L; Ponikowski P
Kardiol Pol; 2020 Aug; 78(7-8):811-817. PubMed ID: 32687267
[No Abstract] [Full Text] [Related]
38. Response to the editorial "COVID-19 in patients with cardiovascular diseases": Covid-19 treatment with hydroxychloroquine or chloroquine and azithromycin: A potential risk of Torsades de Pointes.
Funck-Brentano C; Salem JE; Nguyen LS; Drici MD; Roden DM
Arch Cardiovasc Dis; 2020 May; 113(5):367-368. PubMed ID: 32331979
[No Abstract] [Full Text] [Related]
39. A Call for Randomized Controlled Trials to Test the Efficacy of Chloroquine and Hydroxychloroquine as Therapeutics against Novel Coronavirus Disease (COVID-19).
Keshtkar-Jahromi M; Bavari S
Am J Trop Med Hyg; 2020 May; 102(5):932-933. PubMed ID: 32247318
[No Abstract] [Full Text] [Related]
40. Chloroquine and hydroxychloroquine in covid-19.
Ferner RE; Aronson JK
BMJ; 2020 Apr; 369():m1432. PubMed ID: 32269046
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
